GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors

<p>Abstract</p> <p>Background</p> <p>GPR17 is a G-protein-coupled receptor located at intermediate phylogenetic position between two distinct receptor families: the P2Y and CysLT receptors for extracellular nucleotides and cysteinyl-LTs, respectively. We previously show...

Full description

Bibliographic Details
Main Authors: Ranghino Graziella, Abbracchio Maria P, Parravicini Chiara, Fantucci Piercarlo
Format: Article
Language:English
Published: BMC 2008-06-01
Series:BMC Bioinformatics
Online Access:http://www.biomedcentral.com/1471-2105/9/263
id doaj-32f04bbc0f2f4df886721f0cc458824b
record_format Article
spelling doaj-32f04bbc0f2f4df886721f0cc458824b2020-11-24T23:51:48ZengBMCBMC Bioinformatics1471-21052008-06-019126310.1186/1471-2105-9-263GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptorsRanghino GraziellaAbbracchio Maria PParravicini ChiaraFantucci Piercarlo<p>Abstract</p> <p>Background</p> <p>GPR17 is a G-protein-coupled receptor located at intermediate phylogenetic position between two distinct receptor families: the P2Y and CysLT receptors for extracellular nucleotides and cysteinyl-LTs, respectively. We previously showed that GPR17 can indeed respond to both classes of endogenous ligands and to synthetic compounds active at the above receptor families, thus representing the first fully characterized non-peptide "hybrid" GPCR. In a rat brain focal ischemia model, the selective <it>in vivo </it>knock down of GPR17 by anti-sense technology or P2Y/CysLT antagonists reduced progression of ischemic damage, thus highlighting GPR17 as a novel therapeutic target for stroke. Elucidation of the structure of GPR17 and of ligand binding mechanisms are the necessary steps to obtain selective and potent drugs for this new potential target. On this basis, a 3-D molecular model of GPR17 embedded in a solvated phospholipid bilayer and refined by molecular dynamics simulations has been the first aim of this study. To explore the binding mode of the "purinergic" component of the receptor, the endogenous agonist UDP and two P2Y receptor antagonists demonstrated to be active on GPR17 (MRS2179 and cangrelor) were then modeled on the receptor.</p> <p>Results</p> <p>Molecular dynamics simulations suggest that GPR17 nucleotide binding pocket is similar to that described for the other P2Y receptors, although only one of the three basic residues that have been typically involved in ligand recognition is conserved (Arg255). The binding pocket is enclosed between the helical bundle and covered at the top by EL2. Driving interactions are H-bonds and salt bridges between the 6.55 and 6.52 residues and the phosphate moieties of the ligands. An "accessory" binding site in a region formed by the EL2, EL3 and the Nt was also found.</p> <p>Conclusion</p> <p>Nucleotide binding to GPR17 occurs on the same receptor regions identified for already known P2Y receptors. Agonist/antagonist binding mode are similar, but not identical. An accessory external binding site could guide small ligands to the deeper principal binding site in a multi-step mechanism of activation. The nucleotide binding pocket appears to be unable to allocate the leukotrienic type ligands in the same effective way.</p> http://www.biomedcentral.com/1471-2105/9/263
collection DOAJ
language English
format Article
sources DOAJ
author Ranghino Graziella
Abbracchio Maria P
Parravicini Chiara
Fantucci Piercarlo
spellingShingle Ranghino Graziella
Abbracchio Maria P
Parravicini Chiara
Fantucci Piercarlo
GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
BMC Bioinformatics
author_facet Ranghino Graziella
Abbracchio Maria P
Parravicini Chiara
Fantucci Piercarlo
author_sort Ranghino Graziella
title GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
title_short GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
title_full GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
title_fullStr GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
title_full_unstemmed GPR17: Molecular modeling and dynamics studies of the 3-D structure and purinergic ligand binding features in comparison with P2Y receptors
title_sort gpr17: molecular modeling and dynamics studies of the 3-d structure and purinergic ligand binding features in comparison with p2y receptors
publisher BMC
series BMC Bioinformatics
issn 1471-2105
publishDate 2008-06-01
description <p>Abstract</p> <p>Background</p> <p>GPR17 is a G-protein-coupled receptor located at intermediate phylogenetic position between two distinct receptor families: the P2Y and CysLT receptors for extracellular nucleotides and cysteinyl-LTs, respectively. We previously showed that GPR17 can indeed respond to both classes of endogenous ligands and to synthetic compounds active at the above receptor families, thus representing the first fully characterized non-peptide "hybrid" GPCR. In a rat brain focal ischemia model, the selective <it>in vivo </it>knock down of GPR17 by anti-sense technology or P2Y/CysLT antagonists reduced progression of ischemic damage, thus highlighting GPR17 as a novel therapeutic target for stroke. Elucidation of the structure of GPR17 and of ligand binding mechanisms are the necessary steps to obtain selective and potent drugs for this new potential target. On this basis, a 3-D molecular model of GPR17 embedded in a solvated phospholipid bilayer and refined by molecular dynamics simulations has been the first aim of this study. To explore the binding mode of the "purinergic" component of the receptor, the endogenous agonist UDP and two P2Y receptor antagonists demonstrated to be active on GPR17 (MRS2179 and cangrelor) were then modeled on the receptor.</p> <p>Results</p> <p>Molecular dynamics simulations suggest that GPR17 nucleotide binding pocket is similar to that described for the other P2Y receptors, although only one of the three basic residues that have been typically involved in ligand recognition is conserved (Arg255). The binding pocket is enclosed between the helical bundle and covered at the top by EL2. Driving interactions are H-bonds and salt bridges between the 6.55 and 6.52 residues and the phosphate moieties of the ligands. An "accessory" binding site in a region formed by the EL2, EL3 and the Nt was also found.</p> <p>Conclusion</p> <p>Nucleotide binding to GPR17 occurs on the same receptor regions identified for already known P2Y receptors. Agonist/antagonist binding mode are similar, but not identical. An accessory external binding site could guide small ligands to the deeper principal binding site in a multi-step mechanism of activation. The nucleotide binding pocket appears to be unable to allocate the leukotrienic type ligands in the same effective way.</p>
url http://www.biomedcentral.com/1471-2105/9/263
work_keys_str_mv AT ranghinograziella gpr17molecularmodelinganddynamicsstudiesofthe3dstructureandpurinergicligandbindingfeaturesincomparisonwithp2yreceptors
AT abbracchiomariap gpr17molecularmodelinganddynamicsstudiesofthe3dstructureandpurinergicligandbindingfeaturesincomparisonwithp2yreceptors
AT parravicinichiara gpr17molecularmodelinganddynamicsstudiesofthe3dstructureandpurinergicligandbindingfeaturesincomparisonwithp2yreceptors
AT fantuccipiercarlo gpr17molecularmodelinganddynamicsstudiesofthe3dstructureandpurinergicligandbindingfeaturesincomparisonwithp2yreceptors
_version_ 1725475960229199872